RNA Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
15.3M
+410.0%
3.0M
-84.7%
19.6M
+2183.1%
860.0K
-93.1%
12.5M
Cost of Revenue
0
0
0
0
0
Gross Profit
15.3M
+410.0%
3.0M
-84.7%
19.6M
+2183.1%
860.0K
-93.1%
12.5M
Operating Expenses
21.9M
-14.3%
25.6M
-30.6%
36.9M
-85.5%
255.3M
+26.9%
201.3M
R&D
13.8M
-10.1%
15.3M
-7.9%
16.7M
-90.0%
166.6M
+7.5%
154.9M
SG&A
8.2M
-20.7%
10.3M
-49.3%
20.3M
-77.2%
88.7M
+91.5%
46.3M
Operating Income
-6629000
+70.7%
-22618000
-30.9%
-17280000
+93.2%
-254478000
-34.8%
-188806000
EBITDA
-6277000
+71.8%
-22275000
-30.0%
-17129000
+93.2%
-252982000
-34.7%
-187750000
Net Income
-4266000
+78.9%
-20186000
-21.4%
-16633000
+93.0%
-237101000
-35.9%
-174442000
EPS (Basic)
$-0.25
+78.8%
$-1.18
-21.6%
$-0.97
+37.0%
$-1.54
-21.3%
$-1.27
EPS (Diluted)
$-0.25
+78.8%
$-1.18
-21.6%
$-0.97
+37.0%
$-1.54
-21.3%
$-1.27
Shares (Diluted)
17.0M
-0.4%
17.1M
+0.0%
17.1M
-88.9%
154.1M
+11.7%
137.9M
Atrium Therapeutics (RNA) — Financials